Small number of patients. Encouraging results. Just how you wrap the results when you are BP.
It took them a month to see encouraging results and a number of patients leaving the hospital. And that without placebo, even for the "moderate patients".
I really like our phase 2 mild/moderate study...
gf
Working with pharmaceutical company Gilead Sciences, Remdesivir's manufacturer and sponsor of the studies, Houston Methodist Hospital was the fifth site in the U.S. to join the clinical trials and has been enrolling and treating patients since mid-March. Initially, five patients received early access to Remdesivir on a compassionate use basis, and since being activated as a clinical trial site, more than 35 patients have been enrolled.
The two Phase 3 clinical trials at Houston Methodist are randomized, open-label, multicenter studies and are treating patients with moderate to severe symptoms to evaluate the safety and efficacy of Remdesivir in adults diagnosed with COVID-19. One study is for patients with moderate COVID-19 and tests either a 5-day or 10-day Remdesivir treatment. The second study is evaluating a 10-day course of Remdesivir for patients with severe COVID-19, including those on mechanical ventilation.
Infectious diseases physician Kevin A. Grimes, M.D., M.P.H., and Perez are leading efforts for both the clinical trials at Houston Methodist and say they've been encouraged by the results.
Perez says early results at Houston Methodist have been promising, courses have been well tolerated, and a number of COVID-19 patients who have undergone treatment with Remdesivir are showing signs of recovery and have been released from the hospital to go home. While it's too early to tell, she says there also are indications that treatment with Remdesivir can possibly stave off being intubated.
It took them a month to see encouraging results and a number of patients leaving the hospital. And that without placebo, even for the "moderate patients".
I really like our phase 2 mild/moderate study...
gf
Working with pharmaceutical company Gilead Sciences, Remdesivir's manufacturer and sponsor of the studies, Houston Methodist Hospital was the fifth site in the U.S. to join the clinical trials and has been enrolling and treating patients since mid-March. Initially, five patients received early access to Remdesivir on a compassionate use basis, and since being activated as a clinical trial site, more than 35 patients have been enrolled.
The two Phase 3 clinical trials at Houston Methodist are randomized, open-label, multicenter studies and are treating patients with moderate to severe symptoms to evaluate the safety and efficacy of Remdesivir in adults diagnosed with COVID-19. One study is for patients with moderate COVID-19 and tests either a 5-day or 10-day Remdesivir treatment. The second study is evaluating a 10-day course of Remdesivir for patients with severe COVID-19, including those on mechanical ventilation.
Infectious diseases physician Kevin A. Grimes, M.D., M.P.H., and Perez are leading efforts for both the clinical trials at Houston Methodist and say they've been encouraged by the results.
Perez says early results at Houston Methodist have been promising, courses have been well tolerated, and a number of COVID-19 patients who have undergone treatment with Remdesivir are showing signs of recovery and have been released from the hospital to go home. While it's too early to tell, she says there also are indications that treatment with Remdesivir can possibly stave off being intubated.
